HEALTHMED, cilt.6, sa.4, ss.1356-1361, 2012 (SCI-Expanded)
Aim: Levosimendan is a new inotropic drug used in acute heart failure for its cardiac contractility increasing effect without increasing myocardial oxygen consumption. Longer QRS duration is an important prognostic indicator independent of the underlying heart disease. In heart failure, presence of a QRS duration >= 120ms is regarded as an indicator of cardiac dyssynchrony. In our study, we investigated the efficiency of levosimendan in cardiac dyssynchrony patients whose QRS duration in ECG is accepted >= 120ms.